124 related articles for article (PubMed ID: 12088336)
1. Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up.
Tuxen MK; Sölétormos G; Dombernowsky P
Scand J Clin Lab Invest; 2002; 62(3):177-88. PubMed ID: 12088336
[TBL] [Abstract][Full Text] [Related]
2. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.
Abu Hassaan SO
Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619933
[TBL] [Abstract][Full Text] [Related]
3. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.
Tuxen MK; Sölétormos G; Dombernowsky P
Br J Cancer; 2001 May; 84(10):1301-7. PubMed ID: 11355938
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125.
Zheng X; Chen S; Li L; Liu X; Liu X; Dai S; Zhang P; Lu H; Lin Z; Yu Y; Li G
J Gynecol Obstet Hum Reprod; 2018 Jun; 47(6):227-230. PubMed ID: 29609043
[TBL] [Abstract][Full Text] [Related]
5. Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma.
Shabana A; Onsrud M
Tumour Biol; 1994; 15(6):361-7. PubMed ID: 7997808
[TBL] [Abstract][Full Text] [Related]
6. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.
Duffy MJ; Bonfrer JM; Kulpa J; Rustin GJ; Soletormos G; Torre GC; Tuxen MK; Zwirner M
Int J Gynecol Cancer; 2005; 15(5):679-91. PubMed ID: 16174214
[TBL] [Abstract][Full Text] [Related]
7. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
Oehler MK; Sütterlin M; Caffier H
Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
[TBL] [Abstract][Full Text] [Related]
8. [Ca-125 in diagnosis and monitoring of patients with ovarian cancer].
Bocheva Y; Bochev P; Ivanov S
Akush Ginekol (Sofiia); 2015; 54(1):11-7. PubMed ID: 25909124
[TBL] [Abstract][Full Text] [Related]
9. Serum human epididymis protein 4 vs. carbohydrate antigen 125 in ovarian cancer follow-up.
Ferraro S; Robbiano C; Tosca N; Panzeri A; Paganoni AM; Panteghini M
Clin Biochem; 2018 Sep; 60():84-90. PubMed ID: 30125544
[TBL] [Abstract][Full Text] [Related]
10. Role of tumour markers in monitoring epithelial ovarian cancer.
Meyer T; Rustin GJ
Br J Cancer; 2000 May; 82(9):1535-8. PubMed ID: 10789720
[TBL] [Abstract][Full Text] [Related]
11. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
12. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer.
Yeh LS; Hung YC; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(6B):3669-71. PubMed ID: 12552974
[TBL] [Abstract][Full Text] [Related]
13. Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer.
Tuxen MK; Sölétormos G; Rustin GJ; Nelstrop AE; Dombernowsky P
Scand J Clin Lab Invest; 2000 Dec; 60(8):713-21. PubMed ID: 11218154
[TBL] [Abstract][Full Text] [Related]
14. Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.
Gu Z; He Y; Zhang Y; Chen M; Song K; Huang Y; Li Q; Di W
J Transl Med; 2018 May; 16(1):114. PubMed ID: 29716620
[TBL] [Abstract][Full Text] [Related]
15. Utility of PET/CT in the diagnosis of recurrent ovarian cancer depending on CA 125 serum level.
Fularz M; Adamiak P; Czepczyński R; Jarząbek-Bielecka G; Rewers A; Kędzia W; Ruchała M
Nuklearmedizin; 2015; 54(4):158-62. PubMed ID: 26076719
[TBL] [Abstract][Full Text] [Related]
16. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year.
Low RN; Duggan B; Barone RM; Saleh F; Song SY
Radiology; 2005 Jun; 235(3):918-26. PubMed ID: 15914479
[TBL] [Abstract][Full Text] [Related]
17. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma.
Sevinc A; Camci C; Turk HM; Buyukberber S
Oncology; 2003; 65(1):1-6. PubMed ID: 12837976
[TBL] [Abstract][Full Text] [Related]
18. The clinical value of tumour markers in the management of ovarian cancer.
Rustin GJ
Ann Clin Biochem; 1996 Jul; 33 ( Pt 4)():284-9. PubMed ID: 8836386
[No Abstract] [Full Text] [Related]
19. Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer.
Sugiyama T; Nishida T; Komai K; Nishimura H; Yakushiji M; Nishimura H
Int J Gynaecol Obstet; 1996 Sep; 54(3):251-6. PubMed ID: 8889633
[TBL] [Abstract][Full Text] [Related]
20. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
Sölétormos G; Duffy MJ; Othman Abu Hassan S; Verheijen RH; Tholander B; Bast RC; Gaarenstroom KN; Sturgeon CM; Bonfrer JM; Petersen PH; Troonen H; CarloTorre G; Kanty Kulpa J; Tuxen MK; Molina R
Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
